Searcharxiv⌕ Search

arXiv subjects

Tudor-Stefan Cotet

Publications and source records attributed to Tudor-Stefan Cotet.

2 recordsLinked to original sources

Why risk matters for protein binder design

Bayesian optimization (BO) has recently become more prevalent in protein engineering applications and hence has become a fruitful target of benchmarks. However, current BO comparisons often overlook real-world considerations like risk and cost constraints. In this work, we compare 72 model combinations of encodings, surrogate models, and acquisition functions on 11 protein binder fitness landscapes, specifically from this perspective. Drawing from the portfolio optimization literature, we adopt metrics to quantify the cold-start performance relative to a random baseline, to assess the risk of an optimization campaign, and to calculate the overall budget required to reach a fitness threshold. Our results suggest the existence of Pareto-optimal models on the risk-performance axis, the shift of this preference depending on the landscape explored, and the robust correlation between landscape properties such as epistasis with the average and worst-case model performance. They also highlight that rigorous model selection requires substantial computational and statistical efforts.

cs.LG↗

Learning immune receptor representations with protein language models

Protein language models (PLMs) learn contextual representations from protein sequences and are profoundly impacting various scientific disciplines spanning protein design, drug discovery, and structural predictions. One particular research area where PLMs have gained considerable attention is adaptive immune receptors, whose tremendous sequence diversity dictates the functional recognition of the adaptive immune system. The self-supervised nature underlying the training of PLMs has been recently leveraged to implement a variety of immune receptor-specific PLMs. These models have demonstrated promise in tasks such as predicting antigen-specificity and structure, computationally engineering therapeutic antibodies, and diagnostics. However, challenges including insufficient training data and considerations related to model architecture, training strategies, and data and model availability must be addressed before fully unlocking the potential of PLMs in understanding, translating, and engineering immune receptors.

q-bio.QM↗